ClinicalTrials.Veeva

Menu

Microbiota and Immunoassay in Women With and Without Endometriosis: a Pilot Study

I

Institute of Hospitalization and Scientific Care (IRCCS)

Status

Enrolling

Conditions

Endometriosis-related Pain
Endometriosis

Treatments

Diagnostic Test: Blood, fecal, vaginal and endometrial liquid samples

Study type

Interventional

Funder types

Other

Identifiers

NCT05433909
0009206 u

Details and patient eligibility

About

Endometriosis is an estrogen-dependent chronic inflammatory disease characterized by the presence of endometrial tissue outside the uterine cavity. This pathology has a prevalence of about 5-10% in reproductive-aged women. Endometriosis therapy uses two options: surgical or medical (hormonal) but none can be considered completely resolving. Related signs and symptoms include dysmenorrhea, dyspareunia, infertility, dysuria and dyschezia. In addition to typical gynecological symptoms, gastrointestinal symptoms (bloating, nausea, constipation, diarrhea and vomiting) affect up to 90% of patients with endometriosis. Despite its high prevalence and associated morbidity, its etiology is still unclear and is thought to be multifactorial, and genetic, hormonal, environmental and immunological factors contribute to it. Several studies have shown a significant association between abnormal immune response and maintenance of disease activity in women with endometriosis.

The microbiome contains all the genetic material of microbes, including bacteria, fungi, viruses and Archaea, which live inside the host and regulate various physiological functions. The set of these bacteria, fungi, viruses and Archaea is called a microbiota. The influence of the microbiome on immunomodulation and the development of various inflammatory diseases is well established. Conversely, little is known about the presence and composition of the microbiome in the female reproductive system and its role in the development of endometriosis or other gynecological conditions. Considering the altered inflammatory state typical of endometriosis, it seems logical to postulate a potential role of the microbiome in the etiopathogenesis of this pathology. Interestingly, the microbiome affects estrogen metabolism and estrogen affects the gut microbiome. Since endometriosis is an estrogen-dependent disease, a picture of intestinal dysbiosis resulting in abnormal circulating estrogen levels could potentially contribute to the development of this disease.

Enrollment

50 estimated patients

Sex

Female

Ages

18 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • BMI <30 kg / m2
  • no hormonal therapy (estrogen-progestin, progestogen, GnRH analogues) in progress for at least 1 month
  • the endometriosis group include women who will undergo surgery for endometriosis. The control group include women who will undergo surgery for other gynecological indications (i.e .: abdominal surgical emergencies, tubal infertility, non-endometriotic ovarian cysts) in which the presence of endometriosis will be excluded during the surgery.

Exclusion criteria

  • hormonal therapy in progress (estrogen-progestins, progestins, GnRH analogues)
  • antibiotic and / or probiotic therapy in the 8 weeks before the samples
  • pregnancy
  • menopausal state
  • BMI ≥ 30 kg / m2
  • presence of active systemic diseases, neoplasms, positive clinical history for autoimmune diseases, active vaginosis or positive history for pelvic inflammatory disease

Trial design

Primary purpose

Diagnostic

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

50 participants in 2 patient groups

Endometriosis group
Experimental group
Description:
The endometriosis group will include women who will undergo surgery for endometriosis.
Treatment:
Diagnostic Test: Blood, fecal, vaginal and endometrial liquid samples
Control Group
Experimental group
Description:
The control group include women who will undergo surgery for other gynecological diseases in which the presence of endometriosis will be excluded during the operation.
Treatment:
Diagnostic Test: Blood, fecal, vaginal and endometrial liquid samples

Trial contacts and locations

1

Loading...

Central trial contact

Dhouha Dridi, MD; Laura Buggio, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems